

Michael Paulzen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9191368/publications.pdf>

Version: 2024-02-01

74
papers

1,175
citations

430442

18
h-index

500791

28
g-index

80
all docs

80
docs citations

80
times ranked

1213
citing authors

#	ARTICLE	IF	CITATIONS
1	TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 162-174.	1.3	103
2	Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	1.1	86
3	Cariprazine, a new, orally active dopamine D _{2/3} receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 1141-1159.	1.4	63
4	Serum concentrations of paliperidone versus risperidone and clinical effects. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 797-803.	0.8	43
5	Opiate-Induced Dopamine Release Is Modulated by Severity of Alcohol Dependence: An [18F]Fallypride Positron Emission Tomography Study. <i>Biological Psychiatry</i> , 2011, 70, 770-776.	0.7	34
6	Body mass index (BMI) but not body weight is associated with changes in the metabolism of risperidone; A pharmacokinetics-based hypothesis. <i>Psychoneuroendocrinology</i> , 2016, 73, 9-15.	1.3	31
7	Sertraline in pregnancy – Therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood. <i>Journal of Affective Disorders</i> , 2017, 212, 1-6.	2.0	31
8	The impact of pregnancy on the pharmacokinetics of antidepressants: a systematic critical review and meta-analysis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 431-440.	1.5	31
9	Effect of fluvoxamine augmentation and smoking on clozapine serum concentrations. <i>Schizophrenia Research</i> , 2019, 210, 143-148.	1.1	29
10	Pharmacokinetic Drug-Drug Interactions of Mood Stabilizers and Risperidone in Patients Under Combined Treatment. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 554-561.	0.7	28
11	Pharmacokinetic patterns of risperidone-associated adverse drug reactions. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 1091-1098.	0.8	25
12	Pregnancy exposure to citalopram – Therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 79, 213-219.	2.5	22
13	Pharmacokinetics of risperidone in different application forms – Comparing long-acting injectable and oral formulations. <i>European Neuropsychopharmacology</i> , 2018, 28, 130-137.	0.3	22
14	Antidepressants in breast milk; comparative analysis of excretion ratios. <i>Archives of Women's Mental Health</i> , 2019, 22, 383-390.	1.2	22
15	Excretion of Antipsychotics Into the Amniotic Fluid, Umbilical Cord Blood, and Breast Milk: A Systematic Critical Review and Combined Analysis. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 245-254.	1.0	22
16	Effect of smoking on risperidone pharmacokinetics – A multifactorial approach to better predict the influence on drug metabolism. <i>Schizophrenia Research</i> , 2017, 185, 51-57.	1.1	21
17	Risperidone-induced extrapyramidal side effects. <i>International Clinical Psychopharmacology</i> , 2016, 31, 259-264.	0.9	20
18	Comprehensive Measurements of Intrauterine and Postnatal Exposure to Lamotrigine. <i>Clinical Pharmacokinetics</i> , 2019, 58, 535-543.	1.6	20

#	ARTICLE	IF	CITATIONS
19	Remission of Drug-Induced Hepatitis After Switching from Risperidone to Paliperidone. <i>American Journal of Psychiatry</i> , 2010, 167, 351-352.	4.0	19
20	Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients â€“ thinking of clinically relevant CYP2D6 interactions. <i>Journal of Psychopharmacology</i> , 2016, 30, 803-809.	2.0	19
21	Clinically Significant Drugâ€“Drug Interactions with Agents for Attention-Deficit/Hyperactivity Disorder. <i>CNS Drugs</i> , 2019, 33, 1201-1222.	2.7	19
22	Plasma levels and cerebrospinal fluid penetration by duloxetine in a patient with a non-fatal overdose during a suicide attempt. <i>International Journal of Neuropsychopharmacology</i> , 2009, 12, 1431.	1.0	18
23	Reduced clearance of venlafaxine in a combined treatment with quetiapine. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 85, 116-121.	2.5	18
24	Antidepressant transfer into amniotic fluid, umbilical cord blood & breast milk: A systematic review & combined analysis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 107, 110228.	2.5	18
25	Effects of anticholinergic challenge on psychopathology and cognition in drug-free patients with schizophrenia and healthy volunteers. <i>Psychopharmacology</i> , 2015, 232, 1607-1617.	1.5	17
26	Amisulpride-induced hyperprolactinaemia is not reversed by addition of aripiprazole. <i>International Journal of Neuropsychopharmacology</i> , 2007, 10, 149.	1.0	16
27	The role of striatal dopamine D2/3 receptors in cognitive performance in drug-free patients with schizophrenia. <i>Psychopharmacology</i> , 2018, 235, 2221-2232.	1.5	16
28	Antidepressant polypharmacy and the potential of pharmacokinetic interactions: Doxepin but not mirtazapine causes clinically relevant changes in venlafaxine metabolism. <i>Journal of Affective Disorders</i> , 2018, 227, 506-511.	2.0	16
29	Differences in Duloxetine Dosing Strategies in Smoking and Nonsmoking Patients. <i>Journal of Clinical Psychiatry</i> , 2018, 79, .	1.1	16
30	Pregnancy exposure to quetiapine â€“ Therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood and obstetrical outcomes. <i>Schizophrenia Research</i> , 2018, 195, 252-257.	1.1	15
31	Venlafaxine and O-Desmethylvenlafaxine Concentrations in Plasma and Cerebrospinal Fluid. <i>Journal of Clinical Psychiatry</i> , 2015, 76, 25-31.	1.1	15
32	Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine. <i>Clinical Pharmacokinetics</i> , 2018, 57, 729-737.	1.6	14
33	Clinical response in a risperidone-medicated naturalistic sample: patientsâ€™ characteristics and dose-dependent pharmacokinetic patterns. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017, 267, 325-333.	1.8	13
34	Body mass index as a determinant of clozapine plasma concentrations: A pharmacokinetic-based hypothesis. <i>Journal of Psychopharmacology</i> , 2021, 35, 273-278.	2.0	13
35	Measuring citalopram in blood and central nervous system. <i>International Clinical Psychopharmacology</i> , 2016, 31, 119-126.	0.9	12
36	Sex and body weight are major determinants of venlafaxine pharmacokinetics. <i>International Clinical Psychopharmacology</i> , 2018, 33, 322-329.	0.9	12

#	ARTICLE	IF	CITATIONS
37	Cytochrome P450-mediated interaction between perazine and risperidone: implications for antipsychotic polypharmacy. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1668-1675.	1.1	11
38	Enhancement of atomoxetine serum levels by co-administration of paroxetine. <i>International Journal of Neuropsychopharmacology</i> , 2008, 11, 289-91.	1.0	10
39	Suicide Attempt During Late Pregnancy With Quetiapine. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 343-344.	0.7	10
40	Pharmacokinetic Interaction Between Valproic Acid, Meropenem, and Risperidone. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 90-92.	0.7	10
41	Dopamine D2 Receptor Occupancy Estimated From Plasma Concentrations of Four Different Antipsychotics and the Subjective Experience of Physical and Mental Well-Being in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 550-560.	0.7	10
42	Pregnancy exposure to venlafaxine—Therapeutic drug monitoring in maternal blood, amniotic fluid and umbilical cord blood and obstetrical outcomes. <i>Journal of Affective Disorders</i> , 2020, 266, 578-584.	2.0	10
43	Influence of Kidney Function on Serum Risperidone Concentrations in Patients Treated With Risperidone. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	1.1	10
44	Effects of psychotropic drugs on brain plasticity in humans. <i>Restorative Neurology and Neuroscience</i> , 2014, 32, 163-181.	0.4	9
45	Lamotrigine in pregnancy — therapeutic drug monitoring in maternal blood, amniotic fluid, and cord blood. <i>International Clinical Psychopharmacology</i> , 2015, 30, 249-254.	0.9	9
46	Distribution pattern of mirtazapine and normirtazapine in blood and CSF. <i>Psychopharmacology</i> , 2015, 232, 807-813.	1.5	9
47	How to Treat Hypertension in Venlafaxine-Medicated Patients—Pharmacokinetic Considerations in Prescribing Amlodipine and Ramipril. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 498-501.	0.7	9
48	Duloxetine enters the brain — But why is it not found in the cerebrospinal fluid. <i>Journal of Affective Disorders</i> , 2016, 189, 159-163.	2.0	8
49	Pharmacokinetics of venlafaxine in treatment responders and non-responders: a retrospective analysis of a large naturalistic database. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1109-1116.	0.8	8
50	Cytochrome P450-mediated inhibition of venlafaxine metabolism by trimipramine. <i>International Clinical Psychopharmacology</i> , 2019, 34, 241-246.	0.9	8
51	Pharmacokinetic interactions between clozapine and sertraline in smokers and non-smokers. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020, 127, 303-308.	1.2	8
52	Interaction Between Risperidone, Venlafaxine, and Metronidazole. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 730-733.	0.7	7
53	Pharmacokinetic considerations in antipsychotic augmentation strategies: How to combine risperidone with low-potency antipsychotics. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 76, 101-106.	2.5	7
54	Acute effect of intravenously applied alcohol in the human striatal and extrastriatal D2 /D3 dopamine system. <i>Addiction Biology</i> , 2017, 22, 1449-1458.	1.4	7

#	ARTICLE	IF	CITATIONS
55	Cytochrome P450 2D6 Polymorphism and Its Impact on Decision-Making in Psychopharmacotherapy. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 1465-1467.	1.1	7
56	The negative impact of vitamin D on antipsychotic drug exposure may counteract its potential benefits in schizophrenia. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3193-3200.	1.1	6
57	Pharmacokinetic correlates of venlafaxine: associated adverse reactions. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 851-857.	1.8	5
58	Metamizole but not ibuprofen reduces the plasma concentration of sertraline: Implications for the concurrent treatment of pain and depression/anxiety disorders. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1111-1119.	1.1	5
59	Lack of Smoking Effects on Pharmacokinetics of Oral Paliperidone-analysis of a Naturalistic Therapeutic Drug Monitoring Sample. <i>Pharmacopsychiatry</i> , 2021, 54, 31-35.	1.7	5
60	Effects of the antidepressant mirtazapine on the swimming behaviour and gene expression rate of <i>Danio rerio</i> embryos – Is the sedating effect seen in humans also evident for fish?. <i>Science of the Total Environment</i> , 2021, 792, 148368.	3.9	5
61	Clinically relevant changes in clozapine serum concentrations after breast reduction surgery. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 1059-1060.	1.3	4
62	Antidopaminergic medication in healthy subjects provokes subjective and objective mental impairments tightly correlated with perturbation of biogenic monoamine metabolism and prolactin secretion. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 1125-1138.	1.0	4
63	Treatment Goals for Patients with Schizophrenia – A Narrative Review of Physician and Patient Perspectives. <i>Pharmacopsychiatry</i> , 2021, 54, 53-59.	1.7	4
64	Clinical response in patients treated with once-monthly paliperidone palmitate: analysis of a therapeutic drug monitoring (TDM) database. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2021, 271, 1437-1443.	1.8	4
65	Plasma Risperidone-related Measures in Children and Adolescents with Oppositional Defiant/Conduct Disorders. <i>Clinical Psychopharmacology and Neuroscience</i> , 2020, 18, 41-48.	0.9	4
66	The role of the poor metabolizer genotype CYP2D6 and CYP1A2 phenotype in the pharmacokinetics of duloxetine and venlafaxine – A case report. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020, 127, 354-357.	1.2	3
67	Plasma Levels and Cerebrospinal Fluid Penetration of Venlafaxine in a Patient With a Nonfatal Overdose During a Suicide Attempt. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 398-399.	0.7	2
68	The Effects of Co-prescription of Pantoprazole on the Clozapine Metabolism. <i>Pharmacopsychiatry</i> , 2020, 53, 65-70.	1.7	2
69	Subtherapeutic bupropion and hydroxybupropion serum concentrations in a patient with CYP2C19*1/*17 genotype suggesting a rapid metabolizer status. <i>Pharmacogenomics Journal</i> , 2020, 20, 840-844.	0.9	2
70	Psychopharmaka in Schwangerschaft und Stillzeit. , 2021, , 871-900.		2
71	Effects of body weight, smoking status, and sex on plasma concentrations of once-monthly paliperidone palmitate. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 243-249.	1.3	2
72	Pharmacokinetic Correlates of Once-Monthly Paliperidone Palmitate-Related Adverse Drug Reactions. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1583-1589.	1.6	1

#	ARTICLE	IF	CITATIONS
73	PT705. Therapeutic Drug Monitoring (TDM) in maternal serum, amniotic fluid and umbilical cord blood during pregnancy and delivery. International Journal of Neuropsychopharmacology, 2016, 19, 57-57.	1.0	0
74	Mood Stabilizers: Course and Duration of Therapy, Withdrawal Syndromes, and Resistance to Therapy. , 2020, , 1-24.		0